Alector, Inc. (ALEC)

5.25 +0.44 (+9.15%) 收市：04:00PM EDT

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
https://www.alector.com

版塊: Healthcare
行業: Biotechnology
全職員工: 244

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Arnon Rosenthal Ph.D.	Co-Founder, CEO & Director	1.06M	無	1956
Dr. Marc Grasso M.D.	CFO, Principal Financial Officer & Principal Accounting Officer	728.71k	無	1974
Dr. Gary Romano M.D., Ph.D.	Chief Medical Officer	752.17k	無	1962
Mr. Peter Heutink Ph.D.	Chief Scientific Officer	無	無	無
Katie Hogan	Senior Director of Corporate Communication & Investor Relations	無	無	無
Ms. Danielle Pasqualone J.D., Ph.D.	General Counsel	無	無	無
Ms. Clare Hunt M.B.A.	Chief People Officer	無	無	無
Ms. Kristina Cutter M.P.H.	Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer	無	無	無
Ms. Virginia DeJesus-Rueff M.B.A.	Chief of Staff & Head of Strategy	無	無	無
Ms. Norah Conway	Senior Vice President of Portfolio & Program Management	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

公司管治

截至 2024年4月1日 止，Alector, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：9；董事會：5；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。